维格列汀与二甲双胍治疗新诊断2型糖尿病的临床观察

Clinical observation on treatment of newly diagnosed type 2 diabetes with vildagliptin and mestformin

目的探讨维格列汀联合二甲双胍治疗新诊断2型糖尿病的疗效。方法将79例新诊断2型糖尿病患者随机分为3组,维格列汀组、二甲双胍组,二甲双胍+维格列汀组。治疗12 w后,比较3组治疗前后空腹血糖(FBG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)等指标的变化。结果治疗12 w后,3组FBG、2hPG、HbA1c、HOMA-IR显著下降(P<0.05),FINS显著升高(P<0.05),二甲双胍+维格列汀组比其他两组FBG、2hPG、HbA1c下降更为明显(P<0.05),FINS明显增加(P<0.05)。结论对于新诊断2型糖尿病,维格列汀联合二甲双胍控制血糖效果更为明显。

Objective To discuss the curative effects of vildagliptin and metformin on newly diagnosed type 2 diabetes. Methods Seventy nine cases of newly diagnosed type 2 diabetes were randomly divided into three groups： vildagliptin group （27 cases ）, metformin group （26 cases）, and vildagliptin plus metformin group（ 26 cases ）. They received the treatment for 12 w. Comparison was made in the changes in FBG,PG 2 h after the diet, HbAlc, FINS, and HOMA-IR of three groups before and after the treatment. Results After 12-week of treatment, the level of FBG,2hPG, HbA1 e, and HOMA-IR all significantly deceased in three groups （P 〈 0.05 ） ,while the levels of FINS significantly increased （P 〈 0.05 ）. Compared with the other two groups, the levels of FBG,2hPG, and HbAlc in vildagliptin plus metformin group decreased more significantly （ P 〈 0. 05 ） , while the level of FINS increased more significantly （ P 〈 O. 05 ）. Conclusion Vildagliptin plus metformin have a more obvious effect on the control of blood glucose in patients with ne.wlv diagnosed tvDe 2 diabetes.